A gene therapy has shown significant promise in slowing the progression of Huntington's disease, with some reports indicating a 75% reduction in disease progression. The treatment, which has been described as a breakthrough, has been tested in a trial and appears to have yielded unprecedented results for patients. The specific gene therapy, known as AMT-130, is expected to be submitted to the FDA following the successful trial.